BDTX-1535, a CNS penetrant, irreversible inhibitor of intrinsic and acquired resistance EGFR mutations, demonstrates preclinical efficacy in NSCLC and GBM PDX models.

Tagrisso (osimertinib) - AstraZeneca

BDTX-1535 - Black Diamond Therap

M. Lucas1; M. Merchant2; M. O'Connor3; S. Smith2; A. Trombino2; W.-Y. Zhang2; J.Simon2; S. Eathiraj2; N. Waters2; E. Buck1

Dec 6, 2021